MonTa Biosciences announces completion of patient cohort in our phase I clinical trial

We are pleased to announce the successful completion of the current dose level study involving [...]

Come and meet us and discuss business and partnering at Bio International in San Diego June 3 to 6th

MonTa Biosciences CEO, Simon S Jensen will be attending Bio International in San Diego in [...]

Meet us in San Diego for SITC November 3-5, 2023

MonTa Biosciences will be joining the Society for Immunotherapy and Cancer Therapy (SITC) in San [...]

MonTa Biosciences treat the first patients with the highest dose of MBS8 ever

In the last week of September 2023 we dosed patient number 31 and 32 with [...]

Meet us at BIO International in Boston June 5-8 to discuss clinical development of MBS8

MonTas CEO; Simon S Jensen, PhD, will be joining the biggest partnership conference within Life [...]

New clinical site for MonTas phase I clinical trial in Madrid

We are happy to announce opening of a new clinical site for MonTas phase I [...]

MonTa Biosciences will be presenting very strong data on our immuno oncology technology at the annual meeting of AACR in Orlando

MonTa Biosciences will be presenting very strong data on our immuno oncology technology with our [...]

MonTa Biosciences open clinical sites in Madrid and Bruxelles

MonTa Bisciences have in January opened additionally 4 clinical sites in Madrid and Bruxelles. We [...]

MonTa Biosciences Announces Investment to Complete the Ongoing Phase I Monotherapy Trial on MBS8, and a Combination Phase IB/IIA Trial with MBS8 and a Currently Approved Oncology Drug.

COPENHAGEN, Denmark, October 20, 2022 — MonTa Biosciences, a clinical-stage biotechnology company focused on stimulating [...]

MonTa Biosciences featured in Nature pharmadealmakers magazine

MonTa Biosciences was featured as an upcoming biotech oncology company in Natures edition of pharmadealmakers. [...]

MonTa Biosciences successfully dose first patient in phase I clinical trial

MonTa Biosciences this week successfully enrolled and dosed the first cancer patient in our phase [...]

MonTa Biosciences awarded approval from regulatory agencies to start phase I study

MonTa Biosciences was awarded with positive feedback from the regulatory agency in Denmark to initiate [...]

MonTa Biosciences becomes a Clinical Stage Company

MonTa Biosciences today announced that the company has transitioned from a preclinical to a Clinical [...]

MonTa Biosciences initiates collaboration with NCI under the Nanotechnology Characterization Laboratory program

MonTa Biosciences has successfully gone through a tough selection process and been enrolled into the [...]

MonTa Biosciences successfully completed regulatory advice meeting with the Danish Medicines Agency

MonTa Biosciences have completed our regulatory meeting with the Danish Medicines Agency to align views [...]

MonTa Biosciences recruits Chief Medical Officer Steven Glazer to bring MonTas lead candidate MBS8 into clinical development

Steven Glazer is a well renowned clinical expert and biotech entrepreneur who has a strong [...]

MonTa Biosciences close a Series A investment from existing investors to complete phase I in cancer patients

MonTa Biosciences announced completion of a Series A investment from existing investor Consolidated Biosciences Aps [...]

Selected as an alumni case in the Nordic Mentoring Programme

MonTa Biosceinces was selected among successful biotech startups in the Nordic Mentoring Programme as an [...]

Attending the BioEurope conference in Hamburg

MonTa Biosciences is attending the BioEurope conference in Hamburg to meet with biotech and pharma companies [...]

Presenting data at the cancer immunotherapy SITC conference

MonTa Biosciences is attending the cancer immunotherapy SITC conference in Washington DC to present data on our [...]